Search Results - "Dlugolenski, Keith"

Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation by Kozak, Rouba, Kiss, Tamás, Dlugolenski, Keith, Johnson, David E., Gorczyca, Roxanne R., Kuszpit, Kyle, Harvey, Brian D., Stolyar, Polina, Sukoff Rizzo, Stacey J., Hoffmann, William E., Volfson, Dmitri, Hajós, Mihaly, Davoren, Jennifer E., Abbott, Amanda L., Williams, Graham V., Castner, Stacy A., Gray, David L.

“…Selective activation of dopamine D1 receptors remains a promising pro-cognitive therapeutic strategy awaiting robust clinical investigation. PF-6142 is a key…”
Get full text

Pharmacological disruption of mouse social approach behavior: Relevance to negative symptoms of schizophrenia by Hanks, Ashley N., Dlugolenski, Keith, Hughes, Zoë A., Seymour, Patricia A., Majchrzak, Mark J.

“…•Social approach behavior was not disrupted by NMDA antagonists.•The disruption induced by d-amphetamine was variable and was not reversed by…”
Get full text

Discovery and Lead Optimization of Atropisomer D1 Agonists with Reduced Desensitization by Davoren, Jennifer E, Nason, Deane, Coe, Jotham, Dlugolenski, Keith, Helal, Christopher, Harris, Anthony R, LaChapelle, Erik, Liang, Sidney, Liu, Yue, O’Connor, Rebecca, Orozco, Christine C, Rai, Brajesh K, Salafia, Michelle, Samas, Brian, Xu, Wenjian, Kozak, Rouba, Gray, David

“…The discovery of D1 subtype-selective agonists with drug-like properties has been an enduring challenge for the greater part of 40 years. All known…”
Get full text

Discovery of the Potent and Selective M1 PAM-Agonist N‑[(3R,4S)‑3-Hydroxytetrahydro‑2H‑pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]­pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects by Davoren, Jennifer E, Lee, Che-Wah, Garnsey, Michelle, Brodney, Michael A, Cordes, Jason, Dlugolenski, Keith, Edgerton, Jeremy R, Harris, Anthony R, Helal, Christopher J, Jenkinson, Stephen, Kauffman, Gregory W, Kenakin, Terrence P, Lazzaro, John T, Lotarski, Susan M, Mao, Yuxia, Nason, Deane M, Northcott, Carrie, Nottebaum, Lisa, O’Neil, Steven V, Pettersen, Betty, Popiolek, Michael, Reinhart, Veronica, Salomon-Ferrer, Romelia, Steyn, Stefanus J, Webb, Damien, Zhang, Lei, Grimwood, Sarah

“…It is hypothesized that selective muscarinic M1 subtype activation could be a strategy to provide cognitive benefits to schizophrenia and Alzheimer’s disease…”
Get full text

Design and optimization of selective azaindole amide M 1 positive allosteric modulators by Davoren, Jennifer E., O’Neil, Steven V., Anderson, Dennis P., Brodney, Michael A., Chenard, Lois, Dlugolenski, Keith, Edgerton, Jeremy R., Green, Michael, Garnsey, Michelle, Grimwood, Sarah, Harris, Anthony R., Kauffman, Gregory W., LaChapelle, Erik, Lazzaro, John T., Lee, Che-Wah, Lotarski, Susan M., Nason, Deane M., Obach, R. Scott, Reinhart, Veronica, Salomon-Ferrer, Romelia, Steyn, Stefanus J., Webb, Damien, Yan, Jiangli, Zhang, Lei

Get full text

α5 nAChR modulation of the prefrontal cortex makes attention resilient by Howe, William M., Brooks, Julie L., Tierney, Patrick L., Pang, Jincheng, Rossi, Amie, Young, Damon, Dlugolenski, Keith, Guillmette, Ed, Roy, Marc, Hales, Katherine, Kozak, Rouba

“…A loss-of-function polymorphism in the α5 nicotinic acetylcholine receptor (nAChR) subunit gene has been linked to both drug abuse and schizophrenia. The α5…”
Get full text

Design and optimization of selective azaindole amide M1 positive allosteric modulators by Davoren, Jennifer E., O’Neil, Steven V., Anderson, Dennis P., Brodney, Michael A., Chenard, Lois, Dlugolenski, Keith, Edgerton, Jeremy R., Green, Michael, Garnsey, Michelle, Grimwood, Sarah, Harris, Anthony R., Kauffman, Gregory W., LaChapelle, Erik, Lazzaro, John T., Lee, Che-Wah, Lotarski, Susan M., Nason, Deane M., Obach, R. Scott, Reinhart, Veronica, Salomon-Ferrer, Romelia, Steyn, Stefanus J., Webb, Damien, Yan, Jiangli, Zhang, Lei

“…[Display omitted] Selective activation of the M1 receptor via a positive allosteric modulator (PAM) is a new approach for the treatment of the cognitive…”
Get full text

Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects by Wager, Travis T, Chappie, Thomas, Horton, David, Chandrasekaran, Ramalakshmi Y, Samas, Brian, Dunn-Sims, Elizabeth R, Hsu, Cathleen, Nawreen, Nawshaba, Vanase-Frawley, Michelle A, O’Connor, Rebecca E, Schmidt, Christopher J, Dlugolenski, Keith, Stratman, Nancy C, Majchrzak, Mark J, Kormos, Bethany L, Nguyen, David P, Sawant-Basak, Aarti, Mead, Andy N

“…Dopamine receptor antagonism is a compelling molecular target for the treatment of a range of psychiatric disorders, including substance use disorders. From…”
Get full text

Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects by Wager, Travis T., Chappie, Thomas, Horton, David, Chandrasekaran, Ramalakshmi Y., Samas, Brian, Dunn-Sims, Elizabeth R., Hsu, Cathleen, Nawreen, Nawshaba, Vanase-Frawley, Michelle A., O’Connor, Rebecca E., Schmidt, Christopher J., Dlugolenski, Keith, Stratman, Nancy C., Majchrzak, Mark J., Kormos, Bethany L., Nguyen, David P., Sawant-Basak, Aarti, Mead, Andy N.

“…Dopamine receptor antagonism is a compelling molecular target for the treatment of a range of psychiatric disorders, including substance use disorders. From…”
Get full text